Evidence map›Paper›PMID 33777327›Full record

ArticleStatistical communications in infectious diseases2019

Designing & Conducting Trials To Reliably Evaluate HIV Prevention Interventions.

Thomas R Fleming, Victor DeGruttola, Deborah Donnell

Open access · bronzeAbstract read
In one paragraph

Article in Statistical communications in infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Thomas R FlemingDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Victor DeGruttolaDepartment of Biostatistics, Harvard University, Boston, MA, USA.
Deborah DonnellVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Fred Hutch Cancer Center · USHarvard University · USUniversity of Washington · US

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
Leadership for HIV/AIDS Clinical Trials Networks; HIV Prevention Trials NetworkU01AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DONNELL, DEBORAH J · 2006 to 2010
$28.8M
STATISTICAL ISSUES IN AIDS RESEARCHR37AI029168 · NIAID · UNIVERSITY OF WASHINGTON · PI JAMES P HUGHES · 1999 to 2026
$9.8M
STATISTICAL ISSUES IN AIDS RESEARCHR01AI029168 · NIAID · UNIVERSITY OF WASHINGTON · PI HUGHES, JAMES P · 1989 to 2018
$5.3M
Methods to Advance the HIV Prevention Research AgendaR37AI051164 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI DEGRUTTOLA, VICTOR GERARD · 2012 to 2019
$3.3M
Methods for Long-Term Follow-Up of HIV-Infected PatientsR01AI051164 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI DEGRUTTOLA, VICTOR GERARD · 2002 to 2011
$3.0M
NIAID NIH HHS R01 AI029168NIAID NIH HHS R01 AI051164NIAID NIH HHS R37 AI029168NIAID NIH HHS R37 AI051164NIAID NIH HHS U01 AI068617NIAID NIH HHS UM1 AI068617
6 · The paper itself

Abstract

While much has been achieved, much remains to be accomplished in the science of preventing the spread of HIV infection. Clinical trials that are properly designed, conducted and analyzed are of integral importance in the pursuit of reliable insights about HIV prevention. As we build on previous scientific breakthroughs, there will be an increasing need for clinical trials to be designed to efficiently achieve insights without compromising their reliability and generalizability. Key design features should continue to include: 1) the use of randomization and evidence-based controls, 2) specifying the use of intention-to-treat analyses to preserve the integrity of randomization and to increase interpretability of results, 3) obtaining direct assessments of effects on clinical endpoints such as the risk of HIV infection, 4) using either superiority designs or non-inferiority designs with rigorous non-inferiority margins, and 5) enhancing generalizability through the choice of a relative risk rather than risk difference metric. When interventions have complementary and potentially synergistic effects, factorial designs should be considered to increase efficiency as well as to obtain clinically important insights about interaction and the contribution of component interventions to the efficacy and safety of combination regimens. Key trial conduct issues include timely enrollment of participants at high HIV risk recruited from populations with high viral burden, obtaining 'best real-world achievable' levels of adherence to the interventions being assessed and ensuring high levels of retention. High quality of trial conduct occurs through active rather than passive monitoring, using pre-specified targeted levels of performance with defined methods to achieve those targets. During trial conduct, active monitoring of the performance standards not only holds the trial leaders accountable but also can assist in the development and implementation of creative alternative approaches to increase the quality of trial conduct. Designing, conducting and analyzing HIV prevention trials with the quality needed to obtain reliable insights is an ethical as well as scientific imperative.

Indexed as

factorial designshazard rationon-inferiorityrandomizationrelative risksreplacement endpoints

Identifiers

PMID33777327
PMCPMC7996711
OpenAlexW2962786399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.